Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab +/- Chemo in KRAS+ PD-L1 High NSCLC
NCT04470674Phase 2Withdrawn
- Sponsor
- Shirish M Gadgeel
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Shirish M Gadgeel. Planned start Apr 2021; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04470674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04470674.